Gray Matter n-Acetyl Aspartate Deficits in Secondary Progressive but Not Relapsing-Remitting Multiple Sclerosis

References

1. ↵
   Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430–1438

   CrossRefPubMedWeb of Science
2. ↵
   McDonald WI. Relapse, remission, and progression in multiple sclerosis [editorial]. N Engl J Med 2000;343:1486–1487

   CrossRefPubMedWeb of Science
3. ↵
   Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47–53

   CrossRefPubMedWeb of Science
4. ↵
   Tallan HH. Studies on the distribution of N-acetyl-L-aspartate acid in brain. J Biol Chem 1956;224:41–45

   Web of Science
5. ↵
   Petroff OAC, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate and GABA content of the epileptic human brain. Magn Reson Imaging 1995;13:1197–1211

   CrossRefPubMedWeb of Science
6. ↵
   Pfefferbaum A, Adalsteinsson E, Spielman D, et al. In vivo spectroscopic quantification of the N-acetyl moiety, creatine and choline from large volumes of gray and white matter: effects of normal aging. Magn Reson Med 1999;41:276–284

   CrossRefPubMedWeb of Science
7. ↵
   Pfefferbaum A, Adalsteinsson E, Spielman D, et al. In vivo brain concentrations of N-acetyl compounds, creatine and choline in Alzheimer’s disease. Arch Gen Psychiatry 1999;56:185–192

   CrossRefPubMedWeb of Science
8. ↵
   Adalsteinsson E, Sullivan EV, Kleinhans N, et al. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer’s disease. Lancet 2000;355:1696–1697

   CrossRefPubMedWeb of Science
9. ↵
   Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342–2352

   Abstract/FREE Full Text
10. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650–653

    CrossRefPubMedWeb of Science
11. ↵
    Sarchielli P, Presciutti O, Tarducci R, et al. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. J Neurol 2002;249:902–910

    CrossRefPubMedWeb of Science
12. ↵
    Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–437

    Abstract/FREE Full Text
13. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19

    Abstract/FREE Full Text
14. ↵
    Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology 2002;225:261–268

    PubMedWeb of Science
15. ↵
    Griffin JL, Bollard M, Nicholson JK, Bhakoo K. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed 2002;15:375–384

    CrossRefPubMedWeb of Science
16. ↵
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231

    CrossRefPubMedWeb of Science
17. ↵
    Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965;122:552–568
18. ↵
    Kim DH, Adalsteinsson E, Glover GH, Spielman DM. Regularized higher-order in vivo shimming. Magn Reson Med 2002;48:715–722

    CrossRefPubMedWeb of Science
19. ↵
    Adalsteinsson E, StarLack J, Meyer C, Spielman D. Reduced spatial side lobes in chemical-shift imaging. Magn Reson Med 1999;42:314–323

    CrossRefPubMed
20. ↵
    Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 1979;9:63–66
21. ↵
    Lim KO, Pfefferbaum A. Segmentation of MR brain images into cerebrospinal fluid spaces, white and gray matter. J Comput Assist Tomogr 1989;13:588–593

    PubMedWeb of Science
22. ↵
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452

    Abstract/FREE Full Text
23. ↵
    Hirsch JA, Lenkinski RE, Grossman RI. MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. Am J Neuroradiol 1996;17:1829–1836

    Abstract
24. ↵
    Davie CA, Barker GJ, Thompson AJ, et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736–742

    Abstract/FREE Full Text
25. ↵
    Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385–391

    CrossRefPubMedWeb of Science
26. ↵
    Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol 1999;20:1619–1627

    Abstract/FREE Full Text
27. ↵
    Schiepers C, Van Hecke P, Vandenberghe R, et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 1997;3:8–17

    Abstract/FREE Full Text
28. Blinkenberg M, Bonde C, Holm S, et al. Rate dependence of regional cerebral activation during performance of a repetitive motor task: a PET study. J Cer Blood Flow Metab 1996;16:794–803
29. ↵
    Bakshi R, Miletich RS, Kinkel PR, et al. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998;8:228–234

    CrossRefPubMedWeb of Science
30. ↵
    Rooney WD, Goodkin DE, Schuff N, et al. 1H MRSI of normal appearing white matter in multiple sclerosis. Mult Scler 1997;3:231–237

    Abstract/FREE Full Text
31. ↵
    Husted C, Goodin D, Hugg J, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157–165

    CrossRefPubMedWeb of Science
32. ↵
    De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469–1477

    Abstract/FREE Full Text
33. ↵
    Pan JW, Hetherington HP, Vaughan JT, et al. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T. Magn Reson Med 1996;36:72–77

    PubMedWeb of Science
34. ↵
    Nusbaum AO, Tang CY, Wei T, et al. Whole-brain diffusion MR histograms differ between MS subtypes. Neurology 2000;54:1421–1427

    Abstract/FREE Full Text